Arix Bioscience Share Discussion Threads

[ohisay] 15/3/2021 11:29

Here it is...



LONDON, 15 March 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces Board approval of a share buyback programme of up to £25 million.

The share buyback programme will be limited to the lower of £25 million or 13,555,185 shares, in line with the general authority to repurchase shares, which was granted by shareholders at the most recent annual general meeting held on 4 June 2020. Further details of the share buyback programme will follow.

[n0rbie] 15/3/2021 07:58

Not surprised to see a buyback here considering the huge discount to NAV

[ohisay] 11/3/2021 05:06

I thought ST would update and he has..I'm tempted to double up here especially on any more weakness.

Two items caught my eye.

Furthermore, since Arix’s financial year-end, the company has realised £15.7m selling down stakes in two of its four Nasdaq-quoted investments and increased its shareholding from 2.8 to 4.4 per cent in Paris Stock Exchange-listed GenSight Biologics (SIGHT:PAR), a developer of gene therapy-based treatments of retinal degenerative diseases. The stake in GenSights is worth £12.2m (9p a share) and accounts for a sixth of Arix’s listed portfolio valuation of £70m (52p a share) after adjusting for post period end movements. On the same basis, the unlisted portfolio is worth £62.5m and the proforma cash pile has risen to £185m (136p a share)
Moreover, if the board use their authority to buy back up to 10 per cent of the shares outstanding, then the share price discount is likely to narrow rapidly. Buy.

[ohisay] 10/3/2021 15:02

Indeed but they wanted to make a quick buck .As I recall they sold between 35p and 50p.Act in haste and repent at leisure they say ...

[supernumerary] 10/3/2021 14:58

Woodford's stock-picking skills have always been good, it's his portfolio management that was at fault - putting unlisted companies in an income fund was mad.

Acacia on the other hand could have asked Woodford before they sold SNG, not after.

[ohisay] 10/3/2021 14:44

They were last year but as of this year Woodford has been an advisor.They would never have dumped their SNG shares over the summer had he been around at the time.He was part of the IPO back in 2004 and took part in all their fundraisings ..

[supernumerary] 10/3/2021 10:01

Acacia are wallies - they've been dumping ex-Woodford shares eg SNG at pennies on the dollar just to keep their portfolio tidy.

[rcturner2] 10/3/2021 08:01

Acacia are perfectily entitled as a shareholder to nominate their own directors and put it to the test at an EGM. Then we can see if they have support of the other shareholders or not.

[ohisay] 10/3/2021 06:39

The subtext is they likely want a seat on the board to oversee the cash spend .
TBH most of the issues they raise seem to me to be historic .
I'm perfectly happy with the current board but wouldn't mind an Acacia(aka Woodford )presence.

[rambutan2] 10/3/2021 04:05

I agree:

Acacia Research Corporation, a 19.05% shareholder in Arix Bioscience plc (LSE: ARIX), sent a letter to the Arix Senior Independent Director on 9 March 2021.

Acacia is urging the Arix Board to meet with its largest shareholder ahead of the start date of the recently appointed directors, currently scheduled for April 1, in order to allow for proper discourse on the multitude of shareholder concerns. Arix has a disappointing governance history with 18 different directors in just five years, lacks gender diversity on the Board, and received minimal shareholder approval at AGMs. The disruption at the Board level has led to the departure of key investment professionals. Acacia believes these issues must be addressed on an urgent basis due to the recent receipt of proceeds by a team that now lacks adequate investment professionals.

In its letter, Acacia recommends Arix immediately commence a search for a replacement CEO, restructure the Board with individuals who possess the requisite experience and skills, and in particular, a demonstrated record of successful Board service at companies with sound and stable Board functioning, and hire an experienced team of life sciences investment professionals. No decisions should be made on a reinvestment of the VelosBio (or any other) proceeds until such strategy is implemented.

[djderry] 09/3/2021 12:45

Happy to invest here.I'm a shareholder in Malin and this seems quite similar,a promising pipeline to be sure but I'm suspicious of all 'jam tomorrow 'companies.This certainly isn't one,proven cash realisations and prudent management,as far as I can discern.

[n0rbie] 09/3/2021 08:42

The discount to NAV is crazy

[pinemartin9] 09/3/2021 08:04

Hopefully we will get some good coverage and attract bargain hunters in. Tempted to buy more here. Add to winning positions and all that.

[pinemartin9] 09/3/2021 07:51

Yes very good. There's some real potential here. The new Copenhagen Novo Nordisk spin out sounds exciting. Maybe not see fireworks today, but with a company like this all it takes is one bit of stonking news and the share price can and will jump.

[ohisay] 09/3/2021 07:24

Absolutely stonking results and outlook ..

[eaaxs06] 05/3/2021 13:16

Then it's probably best to turn the computer/phone off until Tuesday morning, Chesil.

Good luck everybody, Sid.

[chesil356] 05/3/2021 08:31

This is definitely one of those companies now where you want to not look at the share price the day before the results!

[ohisay] 21/2/2021 01:50

Pretty clear from this that Acacia isnt going to make the same mistake it did with Synairgen and sell out of Arix anytime soon ..

What started as a request for advice has grown into a partnership. Woodford’s return, revealed in a tearful interview last weekend, is linked to an advisory role on the biotech portfolio now owned by Acacia Research, the Nasdaq-listed company that Press runs. The news of a comeback came with a comment from Press calling Woodford a “truly exceptional investment manager”.

The announcement was met with disbelief from retail investors who lost a minimum of 35 per cent of their money in the failure of Woodford’s fund management empire, and surprise from regulators.

Press is convinced there is still a role for Woodford. He said the stockpicker’s demise had left a “void” in the UK for life sciences investment. “It would be a great tragedy if it was destroyed and not rebuilt,” he added.

“We’ve had to operate with Woodford in the background, and we didn’t like doing that. We decided to come out and make it clear that he has been very helpful to us.”

[chesil356] 15/2/2021 12:22

Looks like the seller has now cleared here imo

[pinemartin9] 12/2/2021 12:27

LONDON, 11 February 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, will announce its annual results for the year ended 31 December 2020, on Tuesday 9th March 2021.

Arix will host a virtual analyst presentation on the same day, at 12:00pm GMT, followed by a Q&A session, accessible via conference call or webcast. The webcast of the presentation will be available on the Company's investor relations website at hxxps://arixbioscience.com/investor-relations/events-presentations.

[arthur_lame_stocks] 09/2/2021 15:11

Sorry I can't help you there.

[snappler] 09/2/2021 14:45

I hold Arix as well and looking for research about the other Neil Woodford backed biotech Investment Company, Malin Corp. The share price is EUR 6. i calculated the fair value around EUR 9, taking the recent share price performance of Immunocore and the sale of kymab into account. Do you know any interesting sites about malin?

[arthur_lame_stocks] 09/2/2021 13:33

I bought a few of these today after ST's write up. With all that cash the investments are in the price at a significant discount to book value.

I like a bit of blue sky investing and hopefully one or more of the other investments will have a successful outcome.